title: Radiation therapy and grade II/III oligodendroglial tumors.
abstract: Radiotherapy has been a longstanding treatment option for low-grade glioma. Improvements in tumor control and radiation-related toxicity may be attributed to advances in neuroimaging as well as radiotherapy planning and delivery. The discovery of various molecular prognostic factors have aided in patient selection for radiotherapy. These prognostic and predictive factors may also play a key role in determining which patients are likely to benefit most from combined systemic therapy and radiation.
authors.affiliation: Department of Radiation Oncology, Princess Margaret Cancer Centre - University Health Network, 610 University Ave, Toronto, ON M5G 2M9, Canada.|Department of Radiation Oncology, University of Toronto, 27 King's College Cir, Toronto, ON M5S, Canada.
authors.forename: Caroline
authors.initials: C
authors.lastname: Chung
authors.affiliation: Department of Radiation Oncology, Princess Margaret Cancer Centre - University Health Network, 610 University Ave, Toronto, ON M5G 2M9, Canada.|Department of Radiation Oncology, University of Toronto, 27 King's College Cir, Toronto, ON M5S, Canada.
authors.forename: Normand
authors.initials: N
authors.lastname: Laperriere
mesh_terms: D001932:Brain Neoplasms / Q000175:diagnosis* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D006801:Humans; D059906:Neuroimaging; D009837:Oligodendroglioma / Q000175:diagnosis / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D011881:Radiotherapy, Computer-Assisted / Q000379:methods*
keywords: IMRT; OARs; astrocytoma; chemotherapy; intensity modulated radiotherapy; low-grade glioma; oligodendroglioma; organs at risk; quality of life; radiation necrosis; radiotherapy; temozolomide